Ariad Pharmaceuticals Inc., of Cambridge, Mass., reported its first revenue from cancer drug Iclusig (ponatinib), which was approved in December for use in adults with chronic myelogenous leukemia or Philadelphia chromosome-positive acute lymphoblastic leukemia that is resistant or intolerant to prior tyrosine kinase inhibitor therapy. Net sales totaled $6.4 million for the quarter ending March 31. Ariad posted a net loss for the quarter of $64.7 million, or 36 cents per share, a narrower loss

Astellas Pharma Inc., of Tokyo, and Drais Pharmaceuticals Inc., of Bridgewater, N.J., will repeat for the third time a spinout maneuver that has been successful with two other programs in the past. The companies partnered to develop and commercialize Astellas's compound ASP7035, a vasopressin V2 receptor selective agonist in development for nocturia, by means of a licensing arrangement to a new virtual company, Tacurion Pharma Inc., to be managed by the Drais executive team. InterWest Partners

Success rates doubled for cancer drugs that entered clinical trials in the early 1990s and those that entered the clinic a decade later, even as the number of such compounds increased by 50 percent over the period, according to a new analysis by the Tufts Center for the Study of Drug Development (CSDD). Clinical success rates – the percentage of investigational compounds that eventually obtain FDA approval – for cancer therapeutics rose from 9.9 percent for drugs that entered the clinic in the

Generic drugmakers appear to be winning in the showdown with biologics makers over state legislation that would limit the automatic substitution of future biosimilars. Colorado, Florida and Indiana are the latest states to shoot down a bill that would require notification and recordkeeping if a pharmacy substitutes a biosimilar for the prescribed biologic. The legislation was modeled on principles the Biotechnology Industry Organization (BIO) has identified as core safeguards for patients

After voting 17-1 that data from a National Institutes of Health (NIH)-sponsored animal study were sufficient to approve Amgen Inc.'s Neupogen as a treatment for radiation sickness, two FDA advisory committees told the agency that the data should be applied to all drugs in the same class. With the Biomedical Advanced Research and Development Authority (BARDA) looking to procure a hefty supply of a granulocyte colony-stimulating factor (G-CSF) such as Neupogen for emergency use in case of a

Cel-Sci Corp., of Vienna, Va., reported findings from an efficacy study in a second animal model of rheumatoid arthritis (RA) using its LEAPS technology. The study evaluated the LEAPS vaccine's effect in the Proteoglycan-induced arthritis (PGIA) model of RA with a dominant T helper 1 (Th1) cytokine profile. Disease severity, measured on the basis of the Arthritis Index and histopathology, was significantly suppressed in mice treated with the LEAPS vaccine compared to controls. The reduction in

Janssen Research & Development LLC, of Raritan, N.J., part of Johnson & Johnson, said patients are now enrolling in a multicenter, open-label expanded access program (EAP) in the U.S. for the investigational oral Bruton's Tyrosine Kinase inhibitor ibrutinib, which is being jointly developed by Janssen and Pharmacyclics Inc., of Sunnyvale, Calif. The mantle cell lymphoma (MCL) EAP is available to eligible patients with relapsed or refractory MCL, who could benefit from treatment with ibrutinib

Concert Pharmaceuticals Inc.'s third deal in just over two years with its deuterium-modifying platform brought Celgene Corp. aboard for a single project at first – an up-front payment along with more than $300 million possible in milestone rewards – but with the potential for more compounds that would bring similar financial terms. The focus of the agreement with Summit, N.J.-based Celgene is on cancer and inflammation. Roger Tung, president and CEO of Concert, would not say which area the

Aegerion Pharmaceuticals Inc., of Cambridge, Mass., added Anne M. VanLent to its board. Afraxis Inc., of San Diego, named Carmine Stengone president and CEO, and Christopher Rex chief scientific officer. BioDelivery Sciences International Inc., of Raleigh, N.C., added Thomas W. D'Alonzo to its board. Cleveland BioLabs Inc., of Buffalo, N.Y., added Julia Brown and Anthony Principi to its board, and appointed David Hohn board chairman. IntelGenx Corp., of Saint Laurent, Quebec, named

Armed with a novel technology and a new target – a class of disease modifying therapies that preserve intracellular S-nitrosoglutathione (GSNO), a regulator of organ repair, regeneration and healing – N30 Pharmaceuticals Inc. has quietly evolved from a 2007 start-up into a development-stage biotech with 30 employees. Along the way, the Boulder, Colo.-based company attracted $60 million in private capital and is making steady progress in its goal to increase endogenous nitrous oxide (NO) by

AMAG Pharmaceuticals Inc., of Lexington, Mass., said a new subgroup analysis from IDA-301, a Phase III, randomized, placebo-controlled trial, was presented at the first poster session of the American College of Obstetrics and Gynecology annual meeting in New Orleans. In the full IDA-301 study, 608 adult patients with iron deficiency anemia (IDA) who had failed or could not tolerate oral iron were treated with ferumoxytol and 200 received placebo, with the demographics and all baseline

In the wake of promising preclinical data for its hepatitis B virus (HBV) candidate, Arrowhead Research Corp. shored up its balance sheet in a $36 million private offering to advance pipeline work, including planned clinical trials of ARC-520, an RNAi-based drug in chronic HBV infection. The cash infusion is the largest in Arrowhead's history – the firm pulled in $21 million in a 2006 funding round – and, at the current burn rate, should sustain operations into 2015, long enough to reach

Esperion Therapeutics Inc., of Ann Arbor, Mich., disclosed full results of a Phase II trial of ETC-1002 in patients with Type II diabetes and hypercholesterolemia. The trial met its primary endpoint, demonstrating that ETC-1002 lowered LDL-C by up to 43 percent, and was associated with improvements in control of other cardiometabolic risk factors. ETC-1002 was well tolerated. The data were presented in an oral session at the Arteriosclerosis, Thrombosis, and Vascular Biology 2013 Scientific

Anacor Pharmaceuticals Inc., of Palo Alto, Calif., said Valeant Pharmaceuticals International Inc., of Montreal, agreed that the launch of efinaconazole, its topical product for the treatment of onychomycosis will not occur until after the September 2013 arbitration hearing to resolve the companies' breach of contract dispute. As a result, the preliminary injunction hearing set for May 6 has been cancelled. Anacor previously disclosed a breach of contract dispute with Dow Pharmaceutical

Allergan Inc., of Irvine, Calif., said the FDA's General and Plastic Surgery Devices Panel of the Medical Devices Advisory Committee voted unanimously that the benefits of Juvederm Voluma XC, an injectable hyaluronic acid dermal filler for cheek augmentation to correct age-related volume deficit in the mid-face, outweigh the risks. If approved, Juvederm Voluma XC would be the first dermal filler in the U.S. for that indication. Bristol-Myers Squibb Co., of New York, said the FDA approved a

Researchers have discovered that the TLR5 agonist Entolimod (CBLB502, Cleveland BioLabs Inc.), which is in development as a radioprotective agent, work primarily on receptors in the liver, and that it may be useful to fight liver metastases and, more broadly, as a liver-protective agent. Andrei Gudkov, who is chief scientific officer at Cleveland BioLabs as well as senior vice president of basic science at the Roswell Park Cancer Institute and the paper's corresponding author, told BioWorld

An existing partner with two other deals jumped aboard Ambrx Inc.'s site-specific, antibody drug conjugate (ADC) bandwagon, as Bristol-Myers Squibb Co. provided $15 million up front plus funding for discovery and research, as well as milestone payments of that could total $97 million per oncology product emerging from the collaboration. "I think it is based on the relationship we've built with BMS, but this is a different franchise area, a different portion of our technology platform," said